Black Diamond Therapeutics, Inc. is a precision oncology company focused on the discovery and development of targeted therapies for genetically defined cancers. Founded in 2016 and headquartered in South San Francisco, the company has built its research programs around the concept of allele-specific targeting, seeking to design small molecules that selectively inhibit mutant proteins driving tumor growth while sparing their normal counterparts. By leveraging deep insights into tumor genomics and structure-based drug design, Black Diamond aims to address mutations that have thus far been difficult to drug.
The company’s proprietary functional genomics platform integrates biophysical, cellular and in vivo data to identify clinically relevant tumor alleles and guide the design of precision inhibitors. Black Diamond’s lead candidate, BDTX-189, is an inhibitor of ERBB family exon 20 insertion mutations and is being evaluated in patients with advanced solid tumors. Its second clinical asset, BDTX-063, targets canonical EGFR mutations in non-small cell lung cancer, and the preclinical pipeline includes BDTX-1535, an allosteric inhibitor of KRAS G12C, along with a discovery-stage program aiming at novel oncogenic drivers.
Black Diamond conducts its clinical trials across the United States and collaborates with research centers in Europe and Asia to accelerate patient enrollment and gather diverse real-world data. The company maintains partnerships with academic institutions and leverages external expertise to refine its precision oncology approach. Through these global efforts, Black Diamond seeks to bring new therapeutic options to patients whose tumors harbor specific, actionable mutations.
Under the leadership of President and Chief Executive Officer Reid Huber, Black Diamond has grown its team of scientific, clinical and regulatory experts to support its mission. The company’s board and management team combine experience from major biopharmaceutical firms, start-ups and leading academic medical centers, reflecting a commitment to both rigorous science and patient-centric drug development. As Black Diamond advances its pipeline, it remains dedicated to transforming the treatment landscape for patients with genetically defined cancers.
AI Generated. May Contain Errors.
